首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Intravenous Injection With Antisense Oligodeoxynucleotides Against Angiotensinogen Decreases Blood Pressure in Spontaneously Hypertensive Rats
【24h】

Intravenous Injection With Antisense Oligodeoxynucleotides Against Angiotensinogen Decreases Blood Pressure in Spontaneously Hypertensive Rats

机译:静脉注射抗血管紧张素原的反义寡聚核苷酸可降低自发性高血压大鼠的血压

获取原文
           

摘要

Abstract —In the renin-angiotensin system, renin is known to cleave angiotensinogen to generate angiotensin I, which is the precursor of angiotensin II. Angiotensin II is a vasoactive peptide that plays an important role in blood pressure. On the other hand, the liver is the major organ responsible for the production of angiotensinogen in spontaneously hypertensive rats (SHR). To test the hypothesis that a reduction of angiotensinogen mRNA in the liver by antisense oligodeoxynucleotides (ODNs) may affect both plasma angiotensinogen and angiotensin II levels, as well as blood pressure, we intravenously injected antisense ODNs against rat angiotensinogen coupled to asialoglycoprotein carrier molecules, which serve as an important regulator of liver gene expression, into SHR via the tail vein. The SHR used in the present study were studied at 20 weeks of age and were fed a standard diet throughout the experiment. Plasma angiotensinogen, angiotensin II concentrations, and blood pressure all decreased from the next day until up to 5 days after the injection of antisense ODNs. These concentrations thereafter returned to baseline by 7 days after injection. A reduction in the level of hepatic angiotensinogen mRNA was also observed from the day after injection until 5 days after injection with antisense ODNs. However, in the SHR injected with sense ODNs, plasma angiotensinogen, angiotensin II concentrations, and blood pressure, as well as hepatic angiotensinogen mRNA, did not significantly change throughout the experimental period. Although the exact role of angiotensinogen in hypertension still remains to be clarified, these findings showed that intravenous injection with antisense ODNs against angiotensinogen coupled to asialoglycoprotein carrier molecules targeted to the liver could thus inhibit plasma angiotensinogen levels and, as a result, induce a decrease in blood pressure in SHR.
机译:摘要—在肾素-血管紧张素系统中,已知肾素会裂解血管紧张素原以生成血管紧张素I,这是血管紧张素II的前体。血管紧张素II是一种血管活性肽,在血压中起重要作用。另一方面,肝脏是自发性高血压大鼠(SHR)产生血管紧张素原的主要器官。为了检验以下假设:反义寡脱氧核苷酸(ODN)降低肝脏中血管紧张素原mRNA的含量可能会影响血浆血管紧张素原和血管紧张素II水平以及血压,我们静脉注射了针对大鼠血管紧张素原的反义ODN,并与脱唾液酸糖蛋白载体分子偶联。通过尾静脉进入SHR,是肝脏基因表达的重要调节剂。本研究中使用的SHR在20周龄时进行了研究,并在整个实验过程中接受了标准饮食。从注射反义ODNs的第二天到最多5天,血浆血管紧张素原,血管紧张素II浓度和血压均下降。这些浓度随后在注射后7天恢复到基线。从注射后的第二天到注射反义ODN后的第5天,还观察到肝血管紧张素原mRNA水平的降低。但是,在注射有义OD​​N的SHR中,整个实验期间血浆血管紧张素原,血管紧张素II浓度和血压以及肝血管紧张素原mRNA均未发生明显变化。尽管血管紧张素原在高血压中的确切作用仍有待阐明,但这些发现表明,静脉注射抗血管紧张素原的反义ODN并与靶向肝脏的去唾液酸糖蛋白载体分子偶联可因此抑制血浆血管紧张素原水平,从而导致血浆血管紧张素原水平降低。 SHR中的血压。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号